MPX International Announces Delayed Filing of Interim Financial Statements Pursuant to OSC Blanket Instrument 51-502

NOT FOR DISTRIBUTION TO NEWSWIRE SERVICES IN THE UNITED STATES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS.

TORONTO, May 27, 2020 (GLOBE NEWSWIRE) — MPX International Corporation (“MPX International”, “MPXI” or the “Corporation”) (CSE:MPXI; OTCQX:MPXOF), a multinational diversified cannabis company, announces that it will be delaying the filing and delivery of certain of its continuous disclosure documents, in accordance with Ontario Instrument 51-502 Temporary Exemption from Certain Corporate Finance Requirements of the Ontario Securities Commission (the “Blanket Exemption Order”) which was adopted for the purpose of providing certain filing and other relief to issuers in light of the challenges posted by the COVID-19 pandemic.

The Corporation is relying on the Blanket Exemption Order in delaying the Corporation’s interim financial statements for the three and six month period ended March 31, 2020 and related certifications; and the Corporation’s management discussion and analysis for the three and six month period ended March 31, 2020.

The officers and directors of the Corporation and certain other persons will remain subject to a trading black-out pursuant to which such persons are prohibited from trading in any securities of the Corporation until the end of the second full trading day following the day on which the Required Annual Filings are filed on SEDAR and a corresponding news release is issued by the Corporation.

The Corporation currently intends to make the required interim filings by July 15, 2020.

About MPX International Corporation

MPX International Corporation is a multinational diversified cannabis company focused on developing and operating assets across the global cannabis industry with an emphasis on cultivating, manufacturing and marketing products which include cannabinoids as their primary active ingredient.

Cautionary Statement Regarding Forward-Looking Information

For further information, please contact:

MPX International Corporation
W. Scott Boyes, Chairman, President and CEO
T: +1-416-840-3725
[email protected]

For additional information on MPXI visit our website www.mpxinternationalcorp.com or http://mpxi.tv.